Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19062274 | INHIBITION OF CANCER CELL VIABILITY BY NANOCOMPOSITES OF GRAPHITIC C3N4, Fe2O3, AND MgAl2O4 | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19022909 | SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USE | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19020126 | COMPOSITIONS COMPRISING INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION | January 2025 | September 2025 | Allow | 8 | 0 | 0 | Yes | No |
| 18973027 | SYSTEMS AND METHODS FOR PREPARING AND ADMINISTERING A HYDRATING SUPPLEMENT COMPOSITION | December 2024 | June 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18940954 | ENERGY DRINK COMPOSITION | November 2024 | August 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18798201 | COMPOSITIONS COMPRISING INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION | August 2024 | July 2025 | Abandon | 11 | 2 | 1 | No | No |
| 18785063 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | July 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18785092 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | July 2024 | September 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18759349 | VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITION | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18669046 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | May 2024 | January 2026 | Allow | 20 | 1 | 0 | No | No |
| 18665149 | SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USE | May 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18643713 | PARENTERAL NUTRITION CONTAINING TRACE ELEMENTS | April 2024 | March 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18627020 | SHEET-SHAPED MEMBER | April 2024 | June 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18542993 | COSMETIC COMPOSITIONS AND METHODS OF USE | December 2023 | September 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18386498 | ALKENONE-BASED FORMULATIONS FOR TOPICAL APPLICATIONS | November 2023 | December 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18487486 | Compositions Having Improved Bioavailability of Therapeutics | October 2023 | December 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18475930 | PHARMACEUTICAL FORMULATION OF ODEVIXIBAT | September 2023 | November 2025 | Allow | 25 | 1 | 0 | No | No |
| 18369616 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | September 2023 | May 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18280408 | MALONAMIDES AND THEIR USE AS HERBICIDES | September 2023 | March 2026 | Allow | 30 | 1 | 0 | Yes | No |
| 18206559 | Method of improving psychosocial health | June 2023 | June 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18318697 | VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITION | May 2023 | November 2025 | Allow | 30 | 1 | 0 | No | No |
| 18312333 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | May 2023 | March 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18312375 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | May 2023 | June 2024 | Allow | 13 | 2 | 1 | No | No |
| 18134980 | GREEN METHOD OF PRODUCING CIRCLE-SHAPED SILVER NANOPARTICLES USING ETHYL ACETATE EXTRACT OF URTICA DIOICA LEAVES | April 2023 | January 2026 | Abandon | 33 | 5 | 1 | No | No |
| 18122478 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | March 2023 | March 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18175495 | AFFINITY ILLUDOFULVENE CONJUGATES | February 2023 | December 2024 | Allow | 21 | 2 | 0 | No | No |
| 18112747 | MAIN AGENT UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAME | February 2023 | December 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18100821 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES | January 2023 | June 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18091176 | SHEET-SHAPED MEMBER | December 2022 | December 2023 | Allow | 11 | 1 | 0 | No | No |
| 18086725 | COSMETIC COMPOSITIONS AND METHODS OF USE | December 2022 | September 2023 | Allow | 9 | 0 | 0 | No | No |
| 18002120 | PHYTOSPHINGOSINE DERIVATIVES AS ADJUVANTS IN IMMUNE STIMULATION | December 2022 | November 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 18082311 | MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS | December 2022 | March 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18076012 | LIQUID FORMULATION COMPOSITIONS, MEDICAMENT DELIVERY DEVICES, AND METHODS OF PREPARATION AND USE THEREOF | December 2022 | April 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18071010 | PRETREATMENT DRUG FOR T CELL INFUSION THERAPY FOR IMMUNE-CHECKPOINT INHIBITOR-RESISTANT TUMOR | November 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18047375 | MICROENCAPSULATION OF NICOTINE FOR TOBACCOLESS ORAL ADMINISTRATION | October 2022 | March 2024 | Abandon | 17 | 2 | 1 | No | No |
| 17996413 | METHOD OF TREATING AFFECTIVE DISORDERS AND PERSONALITY DISORDERS | October 2022 | October 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17957640 | DIMETHYLTRIPTAMINE-BASED NASAL SPRAY FOR THE PERSONALISED TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | September 2022 | March 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17915805 | CPG ODN HAVING IMMUNOREGULATORY FUNCTION AND USE THEREOF | September 2022 | February 2026 | Allow | 41 | 2 | 0 | No | No |
| 17902742 | COMPOSITION FOR COSMETICS | September 2022 | August 2023 | Abandon | 12 | 1 | 1 | No | No |
| 17823239 | INHALABLE ANTIMICROBIAL PARTICLES AND METHODS OF MAKING THE SAME | August 2022 | March 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 17821833 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | August 2022 | February 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 17820417 | NOVEL THERMOSTABLE LIPID NANOPARTICLE AND METHODS OF USE THEREOF | August 2022 | March 2026 | Allow | 43 | 1 | 0 | Yes | No |
| 17803480 | Taste-Modulation of Cooling Agents in Beverages | July 2022 | March 2026 | Allow | 43 | 1 | 1 | Yes | No |
| 17871921 | BUFFER-FREE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | July 2022 | September 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17856600 | Therapeutic Textile Articles and Methods of Use | July 2022 | September 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17757736 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | June 2022 | October 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17841813 | HIGH STRENGTH BIOMEDICAL MATERIALS | June 2022 | March 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 17842187 | METHOD OF PREPARING BIOACTIVE SUBSTANCE-ENCAPSULATED ETHOSOME, ETHOSOME COMPOSITION, AND COSMETIC COMPOSITION INCLUDING ETHOSOME COMPOSITION | June 2022 | August 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17838866 | PREPARATIONS FOR CONTROLLED-RELEASE OF HYPOCHLOROUS ACID | June 2022 | September 2024 | Allow | 27 | 1 | 1 | No | No |
| 17784586 | CHOLINE BOLUS COMPOSITIONS FOR RUMINANTS | June 2022 | January 2026 | Allow | 43 | 2 | 0 | No | No |
| 17832805 | METHODS FOR ADHERING TISSUE SURFACES AND MATERIALS AND BIOMEDICAL USES THEREOF | June 2022 | December 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17830813 | Mesh Compositions and Methods of Production | June 2022 | July 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17803311 | Method of treating blepharitis or conjunctivitis | May 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17733216 | TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTS | April 2022 | June 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17720595 | MICROBIAL OIL, PRODUCTION METHOD FOR MICROBIAL OIL, CONCENTRATED MICROBIAL OIL, AND PRODUCTION METHOD FOR CONCENTRATED MICROBIAL OIL | April 2022 | August 2023 | Allow | 16 | 0 | 0 | No | No |
| 17656702 | Compositions Having Improved Bioavailability of Therapeutics | March 2022 | March 2026 | Allow | 48 | 2 | 0 | Yes | No |
| 17669781 | COMPOSITIONS COMPRISING CHOLINE | February 2022 | December 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17632454 | COMPOSITION FOR INHIBITING NERVE CELL INJURY CAUSED BY Aß | February 2022 | October 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17628059 | PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS | January 2022 | September 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17573577 | Method of treating ocular discomfort | January 2022 | February 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17557108 | ANTISEPTIC POLYMER AND SYNTHESIS THEREOF | December 2021 | September 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17547712 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | December 2021 | December 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17617470 | Device in the Form of a Cannabinoid-Based Polymer Matrix | December 2021 | February 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17545331 | Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases | December 2021 | March 2025 | Allow | 39 | 2 | 0 | No | No |
| 17616971 | DNA NANOSTRUCTURE-BASED VACCINES | December 2021 | December 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17457792 | PARASITICIDAL COLLAR COMPRISING ISOXAZOLINE COMPOUNDS | December 2021 | August 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17540277 | Enhanced Rodeferin Broad Spectrum | December 2021 | March 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17539726 | FASTING-MIMICKING DIET PROMOTES CANCER-FREE SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA MODELS | December 2021 | December 2024 | Allow | 37 | 2 | 1 | No | No |
| 17534292 | Stimulation of NK Cell Activity by Using a Combination of Broccoli, Nigella Sativa, Green Tea, and Pterostilbene Alone and Together with Metformin | November 2021 | February 2024 | Allow | 27 | 2 | 0 | No | No |
| 17611968 | ANTI-INFLUENZA VIRUS COMPOSITION, COMPOSITION FOR TREATING RESPIRATORY DISEASES, AND ANTI-AGING COMPOSITION, COMPRISING DARK GINSENG EXTRACT | November 2021 | August 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17515322 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COVID- 19 INFECTION | October 2021 | August 2022 | Allow | 10 | 1 | 0 | No | No |
| 17607175 | NEW DELIVERY SYSTEM FOR FAT SOLUBLE VITAMINS | October 2021 | May 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17510829 | MODIFIED RELEASE COATED CAPSULES | October 2021 | March 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17602052 | COMPOSITION FOR USE IN IMPROVING ENDOTHELIAL FUNCTION BY ENHANCING FLOW MEDIATED DILATION | October 2021 | June 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17493949 | ORAL AMPHETAMINE COMPOSITION | October 2021 | October 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17485995 | Phenylethanoid Glycoside Extract from Acanthus Ilicifolius L., Preparation Method thereof and Use as Anti-liver Injury Medicament | September 2021 | June 2025 | Allow | 44 | 1 | 1 | No | No |
| 17483070 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | September 2021 | January 2024 | Abandon | 28 | 2 | 1 | No | No |
| 17440009 | SAPONIN-BASED VACCINE ADJUVANTS | September 2021 | May 2025 | Allow | 44 | 2 | 1 | No | No |
| 17472611 | DI-ISOPROPYL-PHOSPHINOYL-ALKANES (DAPA) COMPOUNDS AS TOPICAL AGENTS FOR THE TREATMENT OF SENSORY DISCOMFORT | September 2021 | April 2023 | Allow | 19 | 3 | 0 | No | No |
| 17447101 | VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALING | September 2021 | January 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17410900 | PHARMACEUTICAL FORMULATION OF ARSENIC TRIOXIDE | August 2021 | December 2022 | Allow | 16 | 2 | 1 | Yes | No |
| 17430554 | ADJUVANT COMPOSITION FOR A VACCINE | August 2021 | January 2026 | Allow | 53 | 1 | 1 | No | No |
| 17397256 | ALKENONE-BASED FORMULATIONS FOR TOPICAL APPLICATIONS | August 2021 | August 2023 | Allow | 24 | 2 | 1 | No | No |
| 17444041 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | July 2021 | June 2023 | Allow | 23 | 1 | 1 | No | No |
| 17372436 | LIQUID FORMULATION COMPOSITIONS, MEDICAMENT DELIVERY DEVICES, AND METHODS OF PREPARATION AND USE THEREOF | July 2021 | October 2022 | Allow | 15 | 0 | 0 | Yes | No |
| 17421312 | NOVEL COMPOSITIONS AND METHODS FOR TREHALOSE PHOSPHOLIPIDS | July 2021 | July 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17365692 | PARENTERAL NUTRITION CONTAINING TRACE ELEMENTS | July 2021 | April 2025 | Abandon | 45 | 5 | 2 | Yes | Yes |
| 17362204 | TOPICAL VITAMIN C COMPOSITION | June 2021 | March 2025 | Allow | 45 | 4 | 1 | Yes | No |
| 17413654 | KRAS VARIANT MRNA MOLECULES | June 2021 | September 2025 | Allow | 51 | 1 | 0 | No | No |
| 17338882 | COMPOSITIONS INCLUDING GINSENOSIDE 20(S)-Rg3 AND METHODS OF USING GINSENOSIDE 20(S)-Rg3 TO INHIBIT ALPHA HERPESVIRUS | June 2021 | January 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17327234 | NANO-PENETRATIVE CANNABINOID OIL BLENDS AND COMPOSITIONS AND METHODS OF FORMULATION THEREOF | May 2021 | October 2022 | Abandon | 17 | 2 | 1 | No | No |
| 17296200 | NANOPARTICLES CONTAINING CELLULAR MEMBRANE AND USES THEREOF | May 2021 | March 2025 | Allow | 45 | 3 | 1 | No | No |
| 17324752 | COMPOSITIONS OF CARDIOLIPIN ADJUVANTS AND METHODS OF USE THEREOF | May 2021 | July 2023 | Allow | 26 | 1 | 1 | No | No |
| 17286134 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | April 2021 | November 2025 | Allow | 55 | 2 | 2 | No | No |
| 17285868 | TLR9 AGONISTS FOR USE IN DOWNREGULATING CLEVER-I EXPRESSION ON ALTERNATIVELY ACTIVATED MACROPHAGES | April 2021 | January 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17229693 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | April 2021 | September 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17226049 | Composition for A Nutraceutical Formulation for Treating Anxiety-Based Disorders | April 2021 | July 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17212408 | COMPOSITIONS FOR MAINTAINING ELECTROLYTE BALANCE AND URINARY TRACT HEALTH | March 2021 | September 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17275603 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | March 2021 | August 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17189309 | SURFACE-MODIFIED EMULSOMES FOR INTRANASAL DELIVERY OF DRUGS | March 2021 | September 2021 | Allow | 7 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANTHOPOLOS, PETER.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ANTHOPOLOS, PETER works in Art Unit 1611 and has examined 517 patent applications in our dataset. With an allowance rate of 55.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner ANTHOPOLOS, PETER's allowance rate of 55.1% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ANTHOPOLOS, PETER receive 2.41 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ANTHOPOLOS, PETER is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.3% benefit to allowance rate for applications examined by ANTHOPOLOS, PETER. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 15.6% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 61.3% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 52.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 48.1% are granted (fully or in part). This grant rate is in the 43% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 52% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.